Galmed Pharmaceuticals LtdNASDAQ:GLMDNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.3787
- TODAY'S CHANGE (%)0.0103 (2.7959%)
- Bid / Lots0.3800/ 1
- Ask / Lots0.4000/ 49
- Open / Previous Close0.3654 / 0.3684
- Day Range
- 52 Week Range
- Volume27,300
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | GLMD |
|---|---|---|
| 09:32 ET | 201 | 0.3654 |
| 09:43 ET | 137 | 0.3654 |
| 09:48 ET | 200 | 0.3654 |
| 10:01 ET | 2423 | 0.3654 |
| 10:12 ET | 1901 | 0.3683 |
| 11:15 ET | 100 | 0.3654 |
| 11:24 ET | 455 | 0.3668 |
| 11:51 ET | 600 | 0.3655 |
| 11:58 ET | 882 | 0.365 |
| 12:03 ET | 555 | 0.3651 |
| 12:09 ET | 1000 | 0.36655 |
| 12:14 ET | 2443 | 0.365 |
| 12:25 ET | 100 | 0.3681 |
| 12:32 ET | 5099 | 0.3684 |
| 01:42 ET | 300 | 0.3746 |
| 01:46 ET | 100 | 0.3791 |
| 01:48 ET | 1272 | 0.37455 |
| 01:55 ET | 2000 | 0.3791 |
| 02:20 ET | 252 | 0.374449 |
| 02:31 ET | 300 | 0.3744 |
| 03:20 ET | 270 | 0.37425 |
| 03:30 ET | 500 | 0.376935 |
| 03:45 ET | 700 | 0.378 |
| 03:48 ET | 4101 | 0.3787 |
Apr 4, 2024
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023, from 5:06PM ET on Thursday Apr 04, 2024 by Dow Jones
5:06PM ET on Thursday Apr 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Galmed Pharmaceuticals Ltd | 2.2M | -0.1x | --- |
Salarius Pharmaceuticals Inc | 2.2M | -0.1x | --- |
CNS Pharmaceuticals Inc | 2.2M | 0.0x | --- |
VG Life Sciences Inc | 2.1M | 0.0x | --- |
Dermata Therapeutics Inc | 2.0M | -0.1x | --- |
Bio Path Holdings Inc | 2.4M | -0.1x | --- |
Company Information
Galmed Pharmaceuticals is a Israeli-based clinical-stage biopharmaceutical company.The activiti of the Company is focused on the development therapy for treating liver diseases. Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).
Contact Information
- Headquarters
- 16 Tiomkin StreetTEL AVIV-YAFO, Israel 6578317
- Phone
- ---
- Fax
- ---
Executives
- President, Chief Executive Officer, Director
- Allen Baharaff
- Chief Financial Officer
- Doron Cohen
- Chief Operating Officer, Data Protection Officer
- Guy Nehemya
- Chief Accounting Officer
- Yohai Stenzler
- Chief Scientific Officer
- Liat Hayardeny
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 6.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.82 |
EPS | $-3.68 |
Book Value | $2.75 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
